NASDAQ$DMRA
Damora Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings ·
Briefing
DMRA Q4 2023 — $50.0M revenue, 27.00 EPS
These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or. Damora Therapeutics Inc reported Q4 2023 results. Diluted EPS came in at $27.00. Net income of $13.0M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $50.0M.
- Diluted EPS: $27.00.
- Net income: $13.0M.
- Operating income: $6K.
Headline financials
Revenue & EPS history
Galecto Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
+7.9%
Avg return
5 days after
-14.2%
Avg return
30 days after
43%
3 / 7 earnings
Positive
+4.3%
Q4 2020
Best reaction
-8.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.3% | +7.6% | -10.2% | |
| Q4 2024 | -1.4% | +56.2% | -43.4% | |
| Q3 2024 | -1.5% | +2.0% | -22.6% | |
| Q2 2024 | -2.1% | +11.5% | +0.9% | |
| Q4 2023 | +2.5% | -11.5% | -10.5% | |
| Q4 2022 | -8.1% | -7.7% | -9.1% | |
| Q4 2020 | +4.3% | -3.0% | -4.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro